compounded semaglutide fda enforcement news today Compound versions of GLP-1 drugs for weight loss halted by The FDA has received reports

There is currently no confirmed evidence that retatrutide causes cancer in humans

Part of the motivation is to protect pharmaceutical patents including Lilly's retatrutide patent but the public health rationale is straightforward: injecting unregulated substances is risky

Another approved use for Trulicity is to reduce the risk of major cardiovascular disease, like heart attack or stroke, in adults with type 2 diabetes with known heart disease or multiple risk factors for heart disease

As the clock ticks down on compliance deadlines, it is critical that compounding pharmacies and telehealth companies that prescribe GLP-1 medications review their practices, including pharmacy relationships, drug fulfillment, and patient-facing materials, to ensure they are prepared to adhere to the FDAs regulations for semaglutide and other compounded drugs

Serving Size: 1 Scoop (approx